---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-061101"
form_type: "8-K"
ticker: "SRZN"
cik: "0001824893"
company_name: "Surrozen, Inc./DE"
filed_at: "2023-11-08T23:59:59+00:00"
generated_at: "2026-06-08T10:32:36.074598+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Surrozen Q3 net loss $10.4M; cash $43.4M; Phase 1a data expected Q1 2024

## Summary
- Net loss $10.4M vs $13.4M prior year; R&D expenses down to $6.1M from $8.6M.
- Cash and securities $43.4M (Sept 30, 2023), down from $53.4M (June 30, 2023); runway into 2025.
- Phase 1a data for SZN-043 and SZN-1326 expected Q1 2024; Phase 1b studies to initiate in 2024.
- Two new USPTO patents granted (Nos. 11/746,150 and 11/773,171) for SZN-1326 and SWAP technology.
- Boehringer Ingelheim partnership: potential $10M milestone in 2024 upon candidate nomination.

## SEC filing metadata
- accession: 0000950170-23-061101
- form_type: 8-K
- ticker: SRZN
- cik: 0001824893
- company_name: Surrozen, Inc./DE
- filed_at: 2023-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1824893/000095017023061101/0000950170-23-061101-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1824893/000095017023061101/srzn-20231108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-061101
- JSON: https://secwatch.observer/filing/0000950170-23-061101.json
- Plain text: https://secwatch.observer/filing/0000950170-23-061101.txt

## Key facts
- Earnings Releases
  Surrozen, Inc./DE reported the third quarter ended September 30, 2023 results: net income $10.4 million.
  - Period: the third quarter ended September 30, 2023
  - Net income: $10.4 million
  - Result: reported results
  source text: Net loss for the third quarter ended September 30, 2023 was $10.4 million, as compared to $13.4 million for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1824893/000095017023061101/0000950170-23-061101-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.